Trav13-2: A Potential Drug Target for Psychiatric Disorders (G28670)

Target Name: TRAV13-2

NCBI ID: G28670

TRAV13-2

Other Name(s): TCRAV8S2 | T cell receptor alpha variable 13-2 | TRAV132 | TCRAV13S2

Trav13-2: A Potential Drug Target for Psychiatric Disorders

Trav13-2 (TCRAV8S2), a protein found in the brain, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

The protein is a key component of the brain and is involved in the formation and maintenance of the blood-brain barrier, which is a critical barrier that separates the brain from the surrounding blood vessels and lymphatic system. Trav13-2 has been shown to regulate the movement of immune cells into the brain, which is important for the immune system's role in maintaining brain health.

Research has also suggested that Trav13-2 may be involved in the development and progression of neurodegenerative diseases. Studies have shown that Trav13-2 levels are reduced in the brains of people with Alzheimer's disease, and that this reduction is associated with the progression of the disease. Similarly, Trav13-2 levels have been shown to be reduced in the brains of people with Parkinson's disease, a neurodegenerative disorder that is characterized by the loss of motor and cognitive function.

In addition to its potential role in neurodegenerative diseases, Trav13-2 has also been shown to be involved in the development and progression of other psychiatric disorders, including depression. Studies have shown that Trav13-2 levels are reduced in the brains of people with major depressive disorder, and that this reduction is associated with the severity of the depression.

Furthermore, Trav13-2 has also been shown to play a role in the regulation of pain perception. Studies have shown that Trav13-2 is involved in the transfer of pain from the skin to the brain, and that this transfer is enhanced in people with certain pain conditions.

In conclusion, Trav13-2 is a protein that has the potential to be a drug target and biomarker for a variety of psychiatric and neurological disorders. Further research is needed to fully understand the role of Trav13-2 in these disorders and to develop effective treatments.

Protein Name: T Cell Receptor Alpha Variable 13-2

Functions: V region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAV13-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV13-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets